Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke

Stroke

Volumn 40, Issue 5, 2009, Pages 1870-1876

  Kozak, Anna ^a   Ergul, Adviye ^a,b   El Remessy, Azza B ^a   Johnson, Maribeth H ^b   Machado, Livia S ^a   Elewa, Hazem F ^a   Abdelsaid, Mohammed ^a   Wiley, Daniel C ^a   Fagan, Susan C ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; GELATINASE A; SODIUM CHLORIDE; VASCULOTROPIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; LAMININ; MATRIX METALLOPROTEINASE; TETRAZOLE DERIVATIVE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STROKE; TREATMENT OUTCOME; ANGIOGENESIS; ANIMAL; ANIMAL BEHAVIOR; BIOSYNTHESIS; BODY WEIGHT; CAPILLARY PERMEABILITY; CEREBRAL ARTERY DISEASE; ENDOTHELIUM CELL; METABOLISM; MICROTUBULE; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BEHAVIOR, ANIMAL; BENZIMIDAZOLES; BLOOD PRESSURE; BODY WEIGHT; BRAIN ISCHEMIA; CAPILLARY PERMEABILITY; ENDOTHELIAL CELLS; INFARCTION, MIDDLE CEREBRAL ARTERY; LAMININ; MALE; MATRIX METALLOPROTEINASES; MICROTUBULES; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, WISTAR; STROKE; TETRAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65549163364     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.537225     Document Type: Article

References (20)

1. Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26:1282-1289.
2. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P. The ACCESS study: evaluation of acute can-desartan cilexetil therapy in stroke survivors. Stroke. 2003;34:1699-1703.
3. Fagan SC, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, Ergul A, Hess DC. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens. 2006;24:535-539.
4. Elewa HF, Kozak A, Johnson MH, Ergul A, Fagan SC. Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection. J Hypertens. 2007;25:855-859.
5. Li JM, Mogi M, Iwanami J, Min LJ, Tsukuda K, Sakata A, Fujita T, Iwai M, Horiuchi M. Temporary pretreatment with the angiotensin II type 1 receptor blocker, valsartan, prevents ischemic brain damage through an increase in capillary density. Stroke. 2008;39:2029-2036.
6. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20: 84-91.
7. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC. Delayed minocycline inhibits ischemia-activated matrix metallopro-teinases 2 and 9 after experimental stroke. BMC Neurosci. 2006;7:56.
8. Borlongan CV, Sanberg PR. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci. 1995;15:5372-5378.
9. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472-476.
10. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke. 1986;17:1304-1308.
11. Gohlke P, Von Kugelgen S, Jurgensen T, Kox T, Rascher W, Culman J, Unger T. Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats. J Hypertens. 2002;20: 909-918.
12. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF. Matrix metalloproteinase-2,-9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium. 2006;13:227-231.
13. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin MS, Ahn TH, Choi IS, Shin EK. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003;42:905-910.
14. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, Wang X, Lo EH. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12:441-445.
15. Sano H, Hosokawa K, Kidoya H, Takakura N. Negative regulation of VEGF-induced vascular leakage by blockade of angiotensin II type 1 receptor. Arterioscler Thromb Vasc Biol. 2006;26:2673-2680.
16. Thored P, Wood J, Arvidsson A, Cammenga J, Kokaia Z, Lindvall O. Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. Stroke. 2007;38:3032-3039.
17. Brdon J, Kaiser S, Hagemann F, Zhao Y, Culman J, Gohlke P. Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke. J Hypertens. 2007;25:187-196.
18. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav. 2007;87:179-197.
19. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, Sakanaka M,
20. Shiuchi T, Horiuchi M. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation. 2004;110: 843-848.